Skip to main content

Table 3 Hazard ratiosa according to tertiles of serum 25(OH)D and time between diagnosis and blood collection

From: Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study

  Serum 25(OH)D
  Continuous Categorized
  per 10 nmol/L decrement < 35 nmol/L 35-55 nmol/L ≥ 55 nmol/L
Outcome No.
(events)
HR 95% CI P trend b No.
(events)
HR 95% CI No.
(events)
HR 95% CI No.
(events)
HR 95% CI
Overall mortality              
   All 1,265 (174) 1.08 1.00 to 1.17 0.07 422 (82) 1.55 1.00 to 2.39 397 (44) 0.72 0.45 to 1.17 446 (48) 1.00 -
   < 2 years 1,249 (172) 1.09 1.00 to 1.17 0.05 418 (82) 1.57 1.01 to 2.43 394 (44) 0.75 0.46 to 1.22 437 (46) 1.00 -
   < 1 year 1,093 (151) 1.13 1.03 to 1.22 0.02 375 (77) 1.81 1.11 to 2.94 353 (39) 0.82 0.48 to 1.42 365 (35) 1.00 -
   < 0.5 year 807 (119) 1.15 1.03 to 1.26 0.02 277 (63) 2.19 1.21 to 3.97 275 (33) 0.96 0.50 to 1.83 255 (23) 1.00 -
Distant disease              
   All 1,074 (135) 1.14 1.05 to 1.24 0.006 338 (63) 2.09 1.29 to 3.41 342 (37) 1.16 0.70 to 1.94 394 (35) 1.00 -
   < 2 years 1,059 (133) 1.15 1.05 to 1.25 0.005 335 (63) 2.11 1.30 to 3.45 339 (37) 1.17 0.70 to 1.95 385 (33) 1.00 -
   < 1 year 925 (119) 1.15 1.05 to 1.26 0.007 298 (59) 2.24 1.32 to 3.79 302 (32) 1.28 0.74 to 2.22 325 (28) 1.00 -
   < 0.5 year 685 (95) 1.13 1.01 to 1.25 0.05 219 (48) 2.16 1.18 to 3.98 235 (25) 1.12 0.60 to 2.10 231 (22) 1.00 -
  1. 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; HR, hazard ratio.
  2. a Stratified by age at diagnosis and season, adjusted for tumor size, nodal status, metastases, tumor grade, estrogen/progesterone receptor status, diabetes, mode of detection.
  3. b Calculated by using serum 25(OH)D as a continuous variable.